Monoclonal Antibody Custom Service Market is anticipated to register a CAGR of 5.90% to hit USD 1,045.97 million during the forecast period 2022-2030
The Monoclonal Antibody Custom Service Market is projected to reach USD 1,045.97 million by 2030 at 5.90% CAGR during the forecast period 2022-2030. Monoclonal antibodies are a subset of cells that develop from a single ancestral cell by cell division. The identical progeny of a hybridoma is used to create the monoclonal class of antibodies. These antibodies, which are produced from a single clone and may be grown forever, are extremely specific for a specific area of the body. Monoclonal antibodies distinguish between certain epitopes by binding to antigens, which offers defense against pathogenic organisms.
The growth of the monoclonal antibody custom service market is attributed to the increasing investment in research & development, rising prevalence of chronic and infectious diseases, and increasing demand for personalized medicine. However, high cost of the monoclonal antibody services is anticipated to hamper the market growth.
The COVID-19 pandemic has disrupted the supply chain and interrupted the entire value chain of the monoclonal antibody custom service market, right from raw material procurement to manufacturing, packaging, and distribution. With several manufacturers having the requirement of raw material and end-product stock, the impact does not seem high for a short duration. Furthermore, the COVID-19 pandemic has impacted the production scenario globally. It has changed the business environment for numerous organizations across the globe. Additionally, the COVID-19 pandemic has positively impacted the region, it has changed the business environment for numerous organizations across the globe. Additionally, the COVID-19 pandemic has also created opportunities for players to make some critical strategic decisions. For instance, in March 2021, Y-Biologics (South Korea) and Pierre Fabre (France) announced a strategic research collaboration and optional license agreement to develop targets for immune-oncology. Therefore, such collaborations are anticipated to positively impact the region of the global market during the forecast period Moreover, increased demand and limited supply have led to restrictions in monoclonal antibody custom services worldwide.
Moreover, the increased demand for monoclonal antibody custom services during the COVID-19 pandemic has caused a ripple effect throughout global healthcare systems. Increased demand and limited supply have led to restrictions in monoclonal antibody custom services worldwide. The increased demand for monoclonal antibody custom services during the COVID-19 pandemic has caused a ripple effect throughout global healthcare systems.
Monoclonal Antibody Custom Service Market Dynamics:
The healthcare infrastructure in developing globally, especially in low-middle income countries. It is driven by increasing funding and investments the healthcare infrastructure as well as in research & development of new drugs and treatments. According to the WHO, grants of approximately USD 33 billion were given put globally in 2018. Out of this amount, majority (65%) was utilized in research. Similarly, the National Institutes of Health (NIH) funding had increased by USD 3.146 billion in 2022 (7.3%) compared to 2021. Therefore, such funding initiatives globally for healthcare research is expected to drive the monoclonal antibody custom service market as monoclonal antibodies stand as a promising treatment tool for several serious diseases.
Production of custom monoclonal antibodies is a highly complex process and requires exceptional expertise and high investments. These antibodies are prepared synthetically for a specific purpose and has to be highly selective to its targets in order to function as intended. There is a dearth of such skilled professionals, especially in middle- and low-income countries which hampers the market growth potential.
Personalized medicine is one of the fastest growing trends observed in the healthcare industry which has changed how diseases are identified, classified, and treated. It is especially being utilized in the area of oncology where custom monoclonal antibodies play a vital role in research and therapeutics. It is estimated that 25% of the drugs approved from 2016-2020 by the Food and Drug Administrations (FDA) were of personalized medicine.
Value Chain Analysis
The value chain analysis for the monoclonal antibody custom service market comprises four major components: research & product development, followed by manufacturing of the products, distribution, and ends with marketing & sales.
The research and development process of antibody therapies provides the foundation for quality products and services. This process consists of heavy brainstorming and requires high knowledge and efficiency. In this process, the product designs are ready, and the manufacturing process of the product starts. In addition to in-house manufacturing, contract manufacturing organizations offering cost-effective turnkey projects are observed in this market. Distribution is a vital part of any industry. In this market, distribution consists of intermediaries and direct selling, among others. The major buyers of the products and services are research institutes, pharmaceutical & biotechnology companies, independent researchers, teaching hospitals, and others. Marketing and sales play a crucial role in the monoclonal antibody custom service market. The marketing and sales strategies are essential in understanding the characteristics of the industry in which one is competing. Additionally, increasing demand for research consumables also raises the competition among the companies.
Global Monoclonal Antibody Custom Service Market Share (%), by Source, 2021Source: MRFR Analysis
Monoclonal Antibody Custom Service Market Segment Overview
The global monoclonal antibody custom service market has been divided based on source, type, and application, and end user.
On the basis of source, the market is segmented into rat/mouse custom monoclonal antibody, rabbit custom monoclonal antibody, camelid custom antibodies, and others.
Rats and mouse are the perfect animal models for the discovery of new antibodies, and rat monoclonal antibodies have various benefits over mouse antibodies. Similar to humans, rats generate the antibody isotypes IgA, IgD, IgE, IgG, and IgM and are capable of recognizing a variety of human proteins as antigens. Rats can stimulate an immune response to mouse antigens and that they are stronger than mice, which results in a higher lymphocyte production and a lower antigen demand.
Rabbit monoclonal antibodies have a consistency similar to that of conventional mouse monoclonal antibodies, but they are more sensitive and selective. Rabbit monoclonal antibodies are developed by immunizing animals, screening for functionality, and then cloning the immunogen-specific antibody genes into high-level mammalian expression vectors. Following extensive cell culture, the recombinant antibodies are subsequently purified with Protein A purification.
Camelid antibodies come from the family of mammals known as Camelidae, which includes llamas, camels, and alpacas. Camelids naturally create antibodies that solely have heavy chains. These unusual heavy chain antibodies, referred to as single domain antibodies, only have one heavy chain variable domain that forms the antigen-binding site (sdAbs or VHHs).
In others monoclonal guinea pig antibody, monoclonal goat antibody, hamster monoclonal antibody, and monoclonal monkey antibody are considered. Guinea pigs are more sensitive than other rodents, which is a crucial characteristic for the research of human diseases. The subfamily Caprinae includes the goat, a species allied to sheep. It is a normal species that is typically far from humans and rodents (e.g., mouse). The hamster is a member of the rodent family Cricetidae. The hamster is one of the most often utilized lab animals for extensive trials and research activities, along with its rodent counterparts, the rat and mouse. NHPs, also referred to as monkeys, are a better source for producing antibodies using the immune library.
On the basis of type, the market is segmented into primary antibodies and secondary antibodies.
An immunoglobulin known as a primary antibody is one that binds specifically to a single protein or other biomolecule of interest for research in order to purify, detect, and measure it. Primary antibodies are produced utilizing mouse, rat, rabbit, goat, and other animal species as hosts, either as polyclonal or monoclonal antibodies. They are created and offered in a variety of formats, from unpurified antigens to crude antiserum. There are also primary antibodies available that have been fused to biotin or fluorescent dyes for often studied targets.
Target antigens can be found, sorted, or purified with the help of a secondary antibody. Given that a small number of host animal species produce the vast majority of primary antibodies, and that almost all of these antibodies belong to the IgG class, it is simple and cost-effective for manufacturers to produce and supply secondary antibodies that are ready for use and compatible with the majority of techniques and detection systems. There are numerous secondary antibody alternatives for purity level, specificity, and label type.
Based on application, the global monoclonal antibody custom service market has been diagnostic application, therapeutic application, and research application.
Monoclonal antibodies can be used to detect the presence of a substance and can be used in immunohistochemistry to identify antigens in fixed tissue sections. They are also used as probes to identify materials in laboratories and are used in home-testing kits for pregnancy or ovulation. Certain monoclonal antibodies label cancer cells to help the immune system more easily identify and eliminate them. MABs function by recognizing and locating particular proteins on cancer cells, Every MAB recognizes a different protein.
There are numerous therapeutic uses for monoclonal antibodies. MAbs are used to treat cancer, bone marrow transplants, organ transplants, autoimmune disorders, cardiovascular disorders, and infectious diseases. Monoclonal antibodies can be used directly to improve the host's immune system. Multiple sclerosis and rheumatoid arthritis are two serious autoimmune disorders. MAbs that target T- and B-lymphocytes have shown some promise in treating rheumatoid arthritis patients in clinical trials.
Monoclonal antibodies are extensively used by scientists today. They are employed either to detect the presence of proteins or to purify the desired protein. Monoclonal antibodies (mAb) are important reagents used in biomedical research, in diagnosis of Hepatitis, AIDs, influenza, herpes simplex, and in treatment of diseases such as infections and cancer.
By End User
Based on end user, the global monoclonal antibody custom service market has been segmented into hospitals, research & academic laboratories, pharmaceutical & biotechnology companies, and others.
A significant end user of diagnostic customized antibody products is hospitals. Government and private hospitals are included in the hospitals sector. Hospitals are using monoclonal antibodies to treat and diagnose COVID-19, cancer, and other diseases.
Antibodies are currently one of the most crucial tools for researching how a protein works in cells. The prevalence of neurodegenerative conditions including Huntington's disease, Multiple Sclerosis, and Parkinson's disease is fueling further neurobiological study. For instance, in order to obtain the exclusive rights to the product portfolio of Spring Bioscience Corporation (US) only for research purposes, Abcam Plc. (UK) and Roche (Switzerland) signed a formal licence agreement in January 2018.
The majority of biopharmaceuticals that selectively target abnormal cells are antibodies. Therefore, to treat chronic diseases like cancer, rheumatic heart disease, and arthritis, several pharmaceutical and biotechnology companies have started to focus on generating advanced antibodies.
Ambulatory surgical centres, clinics and diagnostic laboratories are included in this segment. The modern healthcare facilities known as ambulatory surgery centres, or ASCs, are devoted to providing same-day surgical care, including diagnostic and preventive procedures. ASCs are helping in the treatment, and testing for the COVID-19 pandemic, and other diseases like cancer and heart related diseases.
Global monoclonal antibody custom service market Share (%), by Region, 2021Source: MRFR Analysis
Monoclonal Antibody Custom Service Market Regional Analysis
The global monoclonal antibody custom service market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World.
Key factors attributed to its large market share include developed healthcare infrastructure, growing public and private financing and research grants for producing safe and effective custom antibody products, and the presence of many market players in the region. Additionally, the growing prevalence of the chronic disease is anticipated to boost the monoclonal antibody custom service market as monoclonal antibody custom antibody possesses a high potential to treat such diseases. According to the American Cancer Society, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the US in 2022. Therefore, increasing clinical trials for monoclonal antibody therapies augment market growth.
The extensive research and product approvals in antibody therapies and a growing number of cases of chronic and neurological disorders are the major factors driving the market growth in Europe. For instance, according to the European Society for Medical Oncology, there were an estimated 369,000 new cancer cases and around 1,269,200 cancer deaths found in 2022. The monoclonal custom antibodies have the potential in treating such diseases, and hence these factors will drive the monoclonal antibody custom service market growth in the region.
Asia-Pacific is anticipated to register the highest CAGR of 13.48% over the forecast period. Increasing research and development expenditures by the pharmaceutical and biopharmaceutical companies, rising biotechnology research, and awareness of personalized therapeutics are the major factors that are driving the market growth in Asia-Pacific. Additionally, the regional market is developing rapidly and has witnessed the emergence of many players. In addition, there has been a rise in the quality of research in Asia, which is coupled with increasing research opportunities driven by rapid economic growth in Asia-Pacific.
Rest of the World
The rest of the world accounted for the lowest market share due to limited access, and inadequate healthcare infrastructure. However, there has been a positive growth in the medical industry owing to the increasing R&D expenditures and investments in clinical trials and manufacturing. Extensive research and product approvals in monoclonal antibody services supplement the market growth within the region in the forecast period. For instance, in May 2021, UAE authorized the emergency use of Sotrovimab, an investigational monoclonal antibody drug for the treatment of COVID-19.
The global monoclonal antibody custom service market is distinguished by the presence of numerous global, regional, and local players catering to the increasing application of monoclonal antibody custom service antibodies for clinical trials, increasing research funding and collaborations, and growing antibody-based COVID-19 treatments. Because of increased adoption of advanced medical technologies and continuous development by companies, the global monoclonal antibody custom service market is becoming more profitable.
The prominent players in the global monoclonal antibody custom service market are Thermo Fisher Scientific Inc. (US), GenScript (US), Abnova Corporation (Taiwan), Creative Biolabs (US), Abcam plc (UK), ProMab Biotechnologies, Inc. (US), Inotiv (US), Biolegend, Inc. (US), Sino Biological, Inc. (China), and ProteoGenix (France)
The study covers the existing short-term and long-term market effect, helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in the North America, Europe, Asia-Pacific, and Rest of the World. The report analyzes market drivers, restraints, opportunities, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.
Scope of the Report & Segmentation
Global monoclonal antibody custom service market, by Source
Global monoclonal antibody custom service market, by Type
Global monoclonal antibody custom service market, by Application
Global monoclonal antibody custom service market, by End User
Global monoclonal antibody custom service market, by Region
|Market Size||USD 1,045.97 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Source, Type, Application, End User, and Region|
|Geographies Covered||North America, Europe, Asia-Pacific, Rest of the World|
|Key Vendors||Thermo Fisher Scientific Inc. (US), GenScript (US), Abnova Corporation (Taiwan), Creative Biolabs (US), Abcam plc (UK), ProMab Biotechnologies, Inc. (US), Inotiv (US), Biolegend, Inc. (US), Sino Biological, Inc. (China), and ProteoGenix (France)|
|Key Market Opportunities||Increasing demand for personalized medicine|
|Key Market Drivers||Increasing investment in research & development Rising prevalence of chronic and infectious diseases|
Monoclonal antibody custom service market projected to grow at approximately 5.90% CAGR during the assessment period (2022-2030).
The valuation of the global monoclonal antibody custom service market is estimated to increase to USD 1,045.97 by the end of 2030.
Huge patient population suffering from cancer and autoimmune & inflammatory diseases and increasing government support for research & development are major tailwinds pushing the growth of the global monoclonal antibody custom service market.
North America holds the largest share in the global monoclonal antibody custom service market, followed by Europe and the Asia Pacific, respectively.
Abnova Corporation (Taiwan), GenScript (China), Thermo Fisher Scientific Inc. (US), Abcam PLC (UK), Creative-Biolabs (US), Envigo (US), and ProMab Biotechnologies Inc. (US), are some of the top players operating in the global monoclonal antibody custom service market.